Posted by Michael Wonder on 18 Feb 2026
Cytokinetics announces European Commission approval of Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy
17 February 2026 - European Commission Approval Based on Results of SEQUOIA-HCM.
Cytokinetics today announced that the European Commission has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy in adult patients.
